Show simple item record

dc.contributor.authorSemenkow, Samantha
dc.date.accessioned2017-12-01T23:03:56Z
dc.date.available2017-12-01T23:03:56Z
dc.date.issued2017-03
dc.identifier.urihttp://jhir.library.jhu.edu/handle/1774.2/44593
dc.descriptionThe Studies in Applied Finance series is under the general direction of Prof. Steve H. Hanke, Co-Director of the Johns Hopkins Institute for Applied Economics, Global Health, and Study of Business Enterprise (hanke@jhu.edu) and Dr. Hesam Motlagh (hesamnmotlagh@gmail.com), a Fellow at the Johns Hopkins Institute for Applied Economics, Global Health, and Study of Business Enterprise. This working paper is one in a series on applied financial economics, which focuses on company valuations. The authors are mainly students at the Johns Hopkins University in Baltimore who have conducted their work at the Institute as undergraduate researchers.en_US
dc.description.abstractThis working paper is an in-depth analysis of Kite Pharma, Inc. The analysis examines the economic factors that impact Kite Pharma’s underlying business fundamentals. This analysis is then combined with a proprietary Discounted Cash Flow (P-DCF) model to determine Kite Pharma's financial position. The model will be presented along-side Monte-Carlo simulations to reveal the distribution of probable free cash flows and the potential for future earnings. In addition to these quantitative factors, we I assess the alignment of Kite Pharma’s executives with shareholders based on the company’s proxy report. At the conclusion of this analysis, I aim to clearly convey Kite Pharma’s business strategy and the company’s financial standing to arrive at a sound investment decision.en_US
dc.language.isoen_USen_US
dc.publisherInstitute for Applied Economics, Global Health, and the Study of Business Enterpriseen_US
dc.relation.ispartofseriesStudies in Applied Finance;14
dc.subjectfinanceen_US
dc.subjectinvestment thesisen_US
dc.subjectKite Pharmaen_US
dc.subjectfinancing modelingen_US
dc.subjectpre-profit biotech modelen_US
dc.subjectnet present valueen_US
dc.subjectMonte Carlo simulationen_US
dc.subjectmanagement compensationen_US
dc.titleInvestment Thesis for Kite Pharma, Inc. (Nasdaq: KITE)en_US
dc.typeWorking Paperen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record